CrystalGenomics Inc Market Cap ($22.70 Million)
Market Cap & Net Worth: CrystalGenomics Inc (083790)
CrystalGenomics Inc market cap. CrystalGenomics Inc (KQ:083790) has a market capitalization of $22.70 Million (₩33.49 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24542 globally and #1759 in its home market, demonstrating a -11.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CrystalGenomics Inc's stock price ₩828.00 by its total outstanding shares 40452700 (40.45 Million). Also see CrystalGenomics Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
CrystalGenomics Inc Market Cap History (2015–2026)
CrystalGenomics Inc market cap history from 2015 to 2026. Data shows change from $196.14 Million to $22.70 Million (-16.72% CAGR). Check current stock price of CrystalGenomics Inc for real-time trading data and today's change.
Index Memberships
CrystalGenomics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.01% | #914 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.01% | #914 of 1384 |
Weight: CrystalGenomics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CrystalGenomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CrystalGenomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 083790 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
CrystalGenomics Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $196.14 Million | $6.14 Billion | -$4.85 Billion | 0.03x | N/A |
| 2016 | $234.81 Million | $14.52 Billion | -$2.18 Billion | 0.02x | N/A |
| 2017 | $328.05 Million | $12.18 Billion | -$8.58 Billion | 0.03x | N/A |
| 2018 | $316.18 Million | $13.89 Billion | $6.91 Billion | 0.02x | 0.05x |
| 2019 | $270.49 Million | $14.01 Billion | -$37.59 Billion | 0.02x | N/A |
| 2020 | $327.14 Million | $30.22 Billion | -$9.84 Billion | 0.01x | N/A |
| 2021 | $181.48 Million | $42.38 Billion | -$15.90 Billion | 0.00x | N/A |
| 2022 | $95.95 Million | $4.32 Billion | -$23.87 Billion | 0.02x | N/A |
| 2023 | $76.07 Million | $4.88 Billion | -$48.92 Billion | 0.02x | N/A |
| 2024 | $65.93 Million | $7.25 Billion | -$51.54 Billion | 0.01x | N/A |
Competitor Companies of 083790 by Market Capitalization
Companies near CrystalGenomics Inc in the global market cap rankings as of November 4, 2026. Also see CrystalGenomics Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to CrystalGenomics Inc by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5272 globally with a market cap of $2.49 Billion USD ( ₩3.67 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8989 globally with a market cap of $902.70 Million USD ( ₩1.33 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9557 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10371 globally with a market cap of $674.16 Million USD ( ₩994.80 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5272 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.49 Billion | ₩171400.00 |
| #8989 | ST Pharm Co.Ltd | KQ:237690 | $902.70 Million | ₩71400.00 |
| #9557 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
| #10371 | Oscotec Inc | KQ:039200 | $674.16 Million | ₩35400.00 |
Market Capitalization of CrystalGenomics Inc (2015–2026)
Market capitalization of CrystalGenomics Inc from 2015 to today. Between 2015 and today, CrystalGenomics Inc's market cap moved from $196.14 Million to $ 22.70 Million, with a yearly change of -16.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩22.70 Million | -44.32% |
| 2025 | ₩40.76 Million | -38.17% |
| 2024 | ₩65.93 Million | -13.33% |
| 2023 | ₩76.07 Million | -20.71% |
| 2022 | ₩95.95 Million | -47.13% |
| 2021 | ₩181.48 Million | -44.53% |
| 2020 | ₩327.14 Million | +20.95% |
| 2019 | ₩270.49 Million | -14.45% |
| 2018 | ₩316.18 Million | -3.62% |
| 2017 | ₩328.05 Million | +39.71% |
| 2016 | ₩234.81 Million | +19.72% |
| 2015 | ₩196.14 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of CrystalGenomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.70 Million USD |
| MoneyControl | $22.70 Million USD |
| MarketWatch | $22.70 Million USD |
| marketcap.company | $22.70 Million USD |
| Reuters | $22.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more